Literature DB >> 30123560

ALK inhibitors and checkpoint blockade: a cautionary tale of mixing oil with water?

Malini Patel1, Salma K Jabbour1, Jyoti Malhotra1.   

Abstract

Entities:  

Year:  2018        PMID： 30123560      PMCID： PMC6072958          DOI： 10.21037/jtd.2018.06.118

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

1.  Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).

Authors:  David R Spigel; Craig Reynolds; David Waterhouse; Edward B Garon; Jason Chandler; Sunil Babu; Paul Thurmes; Alexander Spira; Robert Jotte; Jin Zhu; Wen Hong Lin; George Blumenschein
Journal:  J Thorac Oncol       Date:  2018-03-06       Impact factor: 15.609

2.  Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

Authors:  Scott Gettinger; Leora Horn; David Jackman; David Spigel; Scott Antonia; Matthew Hellmann; John Powderly; Rebecca Heist; Lecia V Sequist; David C Smith; Philip Leming; William J Geese; Dennis Yoon; Ang Li; Julie Brahmer
Journal:  J Clin Oncol       Date:  2018-03-23       Impact factor: 44.544

Review 3.  Current state of immunotherapy for non-small cell lung cancer.

Authors:  Jyoti Malhotra; Salma K Jabbour; Joseph Aisner
Journal:  Transl Lung Cancer Res       Date:  2017-04

4.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

5.  Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Authors:  Marina Chiara Garassino; Byoung-Chul Cho; Joo-Hang Kim; Julien Mazières; Johan Vansteenkiste; Hervé Lena; Jesus Corral Jaime; Jhanelle E Gray; John Powderly; Christos Chouaid; Paolo Bidoli; Paul Wheatley-Price; Keunchil Park; Ross A Soo; Yifan Huang; Catherine Wadsworth; Phillip A Dennis; Naiyer A Rizvi
Journal:  Lancet Oncol       Date:  2018-03-12       Impact factor: 41.316

Review 6.  Crizotinib resistance: implications for therapeutic strategies.

Authors:  I Dagogo-Jack; A T Shaw
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

7.  Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.

Authors:  Shaodong Hong; Nan Chen; Wenfeng Fang; Jianhua Zhan; Qing Liu; Shiyang Kang; Xiaobo He; Lin Liu; Ting Zhou; Jiaxing Huang; Ying Chen; Tao Qin; Yaxiong Zhang; Yuxiang Ma; Yunpeng Yang; Yuanyuan Zhao; Yan Huang; Li Zhang
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

8.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

9.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

10.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors:  Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531
  10 in total
  5 in total

1.  Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation.

Authors:  Sandip Pravin Patel; Suchita Pakkala; Nathan A Pennell; Karen L Reckamp; Silvana Lanzalone; Anna Polli; Jamal Tarazi; Francisco Robert-Vizcarrondo
Journal:  Oncologist       Date:  2020-02-12

Review 2.  Anaplastic lymphoma kinase-special immunity and immunotherapy.

Authors:  Ye Guo; Hanfei Guo; Yongfei Zhang; Jiuwei Cui
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

Review 3.  Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC).

Authors:  Aaron C Tan; Nick Pavlakis
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

Review 4.  Immunotherapy in oncogene addicted non-small cell lung cancer.

Authors:  Luke McLean; Jose Luis Leal; Benjamin J Solomon; Thomas John
Journal:  Transl Lung Cancer Res       Date:  2021-06

5.  The future of cancer immunotherapy: microenvironment-targeting combinations.

Authors:  Yonina R Murciano-Goroff; Allison Betof Warner; Jedd D Wolchok
Journal:  Cell Res       Date:  2020-05-28       Impact factor: 25.617
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.